HUTCHMED Ltd (HCM) Form 6-K — Oct 26, 2026
HUTCHMED reported positive SAFFRON global Phase III results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO, presented at the ESMO Presidential Symposium and published in the New England Journal of Medicine. The combination cut the risk of progression or death by 45% (PFS HR 0.55, p<0.001) and the risk of death by 32% (OS HR 0.68), extending median overall survival by 4.9 months to 17.8 versus 12.9 months.
Key figures
- Sanovo patients
- 326
- Saffron patients
- 338
- Saffron os hazard ratio
- 0.68
- Saffron median os months
- 17.8
- Saffron pfs hazard ratio
- 0.55
- Saffron median pfs months
- 7.6
- Sanovo os hazard ratio itt
- 0.48
- Sanovo itt pfs hazard ratio
- 0.56
- Sanovo median os months itt
- 44.5
- Sanovo median pfs months itt
- 24.9
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.